Hepatitis B is transmitted through blood and bodily fluids and can pass from mother to child during childbirth. While adults often clear acute infections, up to 90 percent of infants who contract the virus develop lifelong infection, raising the risk of cirrhosis and liver cancer. Because chronic infection is generally incurable, the birth-dose strategy has been viewed by the CDC and major medical societies as essential protection during a period when infants are most vulnerable.
Under current prenatal care guidelines, all pregnant individuals are screened for hepatitis B surface antigen. ACIP members who favored withdrawing the universal birth dose argued that a negative maternal test should allow for later vaccination, saying immediate administration could be postponed without measurable risk. Opponents countered that screening is imperfect—false negatives occur, mothers may acquire infection late in pregnancy, and household contacts can transmit the virus to unvaccinated newborns. Several public-health specialists cautioned that eliminating the blanket recommendation will likely increase infection rates among children.
The American Medical Association described the vote as a step that undermines decades of confidence in a proven intervention and warned of potential confusion among parents and clinicians. Vaccine manufacturers Merck and GSK, whose pediatric hepatitis B products generate limited revenue, both expressed concern that delaying the first dose exposes infants to avoidable harm. A 2024 CDC analysis estimated that the current schedule has prevented more than six million infections and nearly one million hospitalizations since its adoption.
During committee deliberations, some newly appointed members questioned whether sufficient safety studies had been conducted on neonatal vaccination, asserting that brain and immune system development in the first month of life warrants extra caution. Long-term surveillance data, however, have consistently shown the birth-dose vaccine to be safe and effective. According to the CDC’s hepatitis B vaccine information, serious adverse reactions in newborns are exceedingly rare, and benefits outweigh known risks.
The revised recommendation affects timing but not insurance coverage. Andrew Johnson, principal policy analyst at the Centers for Medicare & Medicaid Services, told ACIP that federal law continues to require private insurers, Medicaid, and the Children’s Health Insurance Program to cover Advisory Committee–recommended vaccines with no out-of-pocket cost, regardless of schedule adjustments.
Implementation depends on a forthcoming decision from acting CDC Director Dr. Julie Gerberding. If she endorses ACIP’s vote, hospitals and birthing centers will need to modify standing orders and consent protocols, and pediatric practices will adjust anticipatory guidance for well-baby visits. Should she reject or modify the proposal, the existing universal birth-dose standard would remain in force.
Public-health officials across states are already assessing potential impacts. Some expressed worry that uneven adoption could create confusion: facilities serving high-risk populations may continue universal vaccination, while others might swiftly adopt selective timing. Because hepatitis B often has no early symptoms, a rise in undetected infections could go unnoticed for years before chronic disease manifests, complicating future efforts to trace sources and contain outbreaks.
For now, the debate underscores how changes to expert panels can shift long-established public-health policies. While supporters of the new guidance view it as empowering parental choice, critics stress that decades of real-world evidence confirm the value of vaccinating newborns before hospital discharge. With final CDC approval pending, medical institutions and families await clarity on whether the United States will maintain or retreat from one of its most successful prevention strategies.
Crédito da imagem: Alyssa Pointer | Reuters
